Molecules

Fluorothymidine

Target Proliferation (FLT)Class Nucleoside (thymidine analogue)Other names FLT, alovudine

6ongoing trials
1radiolabelled forms
0approved products
996publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C10H13FN2O4
Molar mass (g/mol)
244.22
Exact mass (Da)
244.0859
XLogP
-0.3
H-bond donors
2
H-bond acceptors
5
Rotatable bonds
2
Heavy atoms
17
InChIKey
UXCAQJAQSWSNPQ-XLPZGREQSA-N
PubChem record
CID 33039 ↗
IUPAC name
1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
SMILES
CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]FLT Syntheses and QC ↗Imaging243.226Phase 2—

Ongoing trials · 6Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
[18F]FLTNCT02392429 · Leukemia / transplant conditioningPhase 2Active, not recruitingNational Cancer Institute (NCI)1
REALIZE · [18F]FLTNCT03633955 · LymphomaPhase 1RecruitingUniversity of Oklahoma1
[18F]FLTNCT03422731 · Leukemia / transplant conditioningPhase 1Active, not recruitingCity of Hope Medical Center1
REVEAL · [18F]FLTNCT03541889 · Leukemia / transplant conditioningPhase 1RecruitingUniversity of Oklahoma1
[18F]FLTNCT02608216 · BreastPhase 1Active, not recruitingUniversity of Pennsylvania1
[18F]FLTNCT00935090 · Brain (glioma, medulloblastoma…)No phaseActive, not recruitingBarbara Ann Karmanos Cancer Institute1

Published results · 1

2026-08TNPET01 · promisingIn triple-negative breast cancer (22 patients), FDG and FLT are reproducible; FDG was chosen. Its drop in uptake after a single cycle predicts the final pathological response better than MRI. Small cohort; validation needed.Clin Cancer Res ↗

PublicationsAll publications in PubMed ↗

996 publications in PubMed for the query below; the most recent:

fluorothymidine[tiab] OR "FLT PET"[tiab]

  1. Combined PET imaging of tumor hypoxia and proliferation in Glioblastoma using a single injection of 18F-FMISO and 18F-FLT: Association with sites of subsequent recurrence Med Phys, 2026
  2. Dual-tracer (18)F-FDG and (18)F-FLT PET/CT for differentiating metastatic lymph nodes from sarcoid involvement in a patient with vulvar squamous cell carcinoma and coexisting pulmonary sarcoidosis Radiol Case Rep, 2026
  3. Dosimetric and Clinical Impact of Bone Marrow-sparing Radiation Therapy for Anal Cancer: A Systematic Review Adv Radiat Oncol, 2026
  4. Comparative diagnostic performance of ¹⁸F-FLT and ¹⁸F-FDG PET for differentiating primary CNS lymphoma from glioblastoma, IDH-wildtype Ann Nucl Med, 2026
  5. FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer Am J Nucl Med Mol Imaging, 2026
  6. A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Clin Cancer Res, 2026
  7. Long-term prognostic value of (18)F-FLT PET/CT versus (18)F-FDG PET/CT in locally advanced oesophageal squamous cell carcinoma: a prospective study Cancer Imaging, 2026
  8. Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial Nat Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Fluorothymidine. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/flt/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.